SUBSCRIBE
SUBSCRIBE

Jill Gartz

Business
TenSixteen Scores $40M to Intercept Disease at its Earliest Stages
TenSixteen Bio launched Thursday with a $40 million Series A financing round funded by Foresite Capital and GV, formerly Google Ventures.
January 28, 2022
 · 
3 min read
 · 
Jill Gartz
Drug Development
Viking X-ALD Study Paused Over Conflicting Phase Interpretations
The FDA is calling the study a phase II trial and says the company must run a rodent genotoxicity study before it can continue.
January 27, 2022
 · 
2 min read
 · 
Jill Gartz
Drug Development
Cortexyme Crashes as Key Alzheimer’s Asset Hit with Clinical Hold
Cortexyme said it plans to provide additional updates pending further talks with the FDA.
January 26, 2022
 · 
3 min read
 · 
Jill Gartz
Biotech Bay
Metagenomi’s Gene Editing Programs Take $175 Million Leap Forward
Metagenomi announced the completion of an oversubscribed $175 million Series B financing round, bringing the company’s total funding to $300 million.
January 25, 2022
 · 
2 min read
 · 
Jill Gartz
The withdrawal request of Pepaxto is under reconsi
Drug Development
Oncopeptides Withdraws Withdrawal of First Marketed Drug Pepaxto
Oncopeptides has discontinued the marketing of Pepaxto drug in the US. But, in a recent turnaround, they decided to withdraw this decision of stopping the production.
January 24, 2022
 · 
2 min read
 · 
Jill Gartz